We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+20.89%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$144M
AUM Growth
-$19.7M
Cap. Flow
-$43.7M
Cap. Flow %
-30.38%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
LITS
Lite Strategy Inc
LITS
+$6.95M

Top Sells

Rank Stock Value
1
IQV icon
IQVIA
IQV
+$33.7M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$9.4M
3
DRTX
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
+$1.32M

Sector Composition

Rank Sector Weight
1 Healthcare 66.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IQV icon
1
IQVIA
IQV
$33.5B
$58.6M 40.72%
1,153,773
-669,802
-37% -$33.7M
DRTX
2
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$40.8M 28.35%
3,030,175
-100,649
-3% -$1.32M
CMRX
3
DELISTED
Chimerix, Inc.
CMRX
$27.9M 19.39%
1,222,943
– –
LITS
4
Lite Strategy Inc
LITS
$35.4M
$8.6M 5.98%
+38,500
New +$6.95M
SRNE
5
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$8M 5.56%
620,700
– –
ICPT
6
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-137,519
Closed -$9.4M

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q1 2014 Portfolio in Review

As of Q1 2014, Aisling Capital held 7 positions worth $144M, down 12% from $164M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Aisling Capital withdrew a net $43.7M in Q1 2014, closing 2 positions and reducing 2 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $9.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 69% a quarter earlier.

Against the trend, Aisling Capital opened a new position in Lite Strategy Inc worth $8.6M.

  • Aisling Capital's largest Q1 2014 buy was Lite Strategy Inc: 38,500 shares worth $8.6M.
  • Aisling Capital's biggest Q1 2014 reduction was IQVIA, cutting an estimated $33.7M.
  • Aisling Capital fully exited Intercept Pharmaceuticals, Inc. in Q1 2014, selling an estimated $9.4M.
  • Aisling Capital's ten largest holdings make up 100% of its $144M portfolio in Q1 2014.
  • Aisling Capital opened 1 new position and closed 2 in Q1 2014.
  • Aisling Capital's portfolio value fell 12% quarter-over-quarter to $144M.

Based on Aisling Capital's 13F filing for Q1 2014, filed 13 May 2014.